NASDAQ · ABCL
Healthcare · Biotechnology
$12.08
Up+$0.26 (+2.20%)
Updated Oct 27, 2026, 6:26 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABCL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
ABCL closed at $12.08 after 21 trading sessions, down 13.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $12.02 | $12.415 | $11.78 | $12.08 | 3.04M |
| Oct 23, 2026 | $11.45 | $11.895 | $11.08 | $11.82 | 3.03M |
| Oct 22, 2026 | $11.985 | $12.23 | $11.205 | $11.37 | 4.28M |
| Oct 21, 2026 | $11.78 | $12.365 | $11.59 | $12.24 | 3.22M |
| Oct 20, 2026 | $11.65 | $11.945 | $11.41 | $11.71 | 4.26M |
| Oct 19, 2026 | $12.045 | $12.28 | $11.75 | $11.93 | 3.14M |
| Oct 16, 2026 | $12.68 | $12.68 | $11.72 | $11.80 | 4.11M |
| Oct 15, 2026 | $11.94 | $12.86 | $11.6915 | $12.68 | 5.76M |
| Oct 14, 2026 | $12.37 | $12.84 | $12.26 | $12.37 | 3.06M |
| Oct 13, 2026 | $12.53 | $12.72 | $12.20 | $12.61 | 3.25M |
| Oct 12, 2026 | $12.71 | $13.055 | $12.43 | $12.635 | 5.76M |
| Oct 9, 2026 | $12.03 | $12.79 | $11.93 | $12.545 | 4.69M |
| Oct 8, 2026 | $12.54 | $12.6299 | $11.89 | $12.02 | 8.52M |
| Oct 7, 2026 | $12.85 | $13.4499 | $12.56 | $12.83 | 5M |
| Oct 6, 2026 | $14.00 | $14.53 | $12.933 | $13.15 | 9.79M |
| Oct 5, 2026 | $13.72 | $13.88 | $13.21 | $13.78 | 4.08M |
| Oct 2, 2026 | $14.095 | $14.303 | $13.66 | $13.74 | 3.71M |
| Oct 1, 2026 | $14.585 | $14.65 | $13.79 | $13.91 | 7.79M |
| Sep 30, 2026 | $14.78 | $15.015 | $14.56 | $14.59 | 4.86M |
| Sep 29, 2026 | $14.23 | $15.00 | $14.10 | $14.82 | 9.11M |
| Sep 28, 2026 | $12.44 | $14.2299 | $12.38 | $13.92 | 7.83M |
The latest Smart Investors Daily articles mentioning ABCL.
Company
Market Activity
Research & News
ABCL research
Company profile and research snapshot.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Buy | — |
| Sep 29, 2026 | JP Morgan | Overweight | — |
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 12, 2026
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
Benzinga · Oct 12, 2026
UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.
Yahoo · Oct 9, 2026
AbCellera Biologics (ABCL) drew fresh attention after disclosing it will present new Phase 1/2 data on its investigational antibody ABCL635 at The Menopause Society’s 2026 Annual Meeting. That clinical spotlight arrives after a sharp run, with AbCellera Biologics posting a 90 day share price return of 84.49% and a year to date share price gain of 265.74%. The 1 year total shareholder return of 126.85% points to strong recent momentum despite earlier long term volatility. Scan other health and...
Yahoo · Oct 8, 2026
Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should track this figure closely, as the drug developer continues to lose money. Its drug programs remain in clinical trials, and it had a net loss of about $0.5 billion over the last twelve months. So how quickly is Recursion spending that cash.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABCL.
